Eli Lilly and Company (NYSE:LLY) Shares Sold by Patriot Financial Group Insurance Agency LLC

Patriot Financial Group Insurance Agency LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 34.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,159 shares of the company's stock after selling 604 shares during the period. Patriot Financial Group Insurance Agency LLC's holdings in Eli Lilly and Company were worth $895,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Algert Global LLC boosted its position in shares of Eli Lilly and Company by 27.9% during the second quarter. Algert Global LLC now owns 504 shares of the company's stock worth $456,000 after acquiring an additional 110 shares during the last quarter. RiverFront Investment Group LLC purchased a new position in shares of Eli Lilly and Company during the second quarter valued at about $256,000. Anchor Investment Management LLC increased its holdings in shares of Eli Lilly and Company by 0.9% in the second quarter. Anchor Investment Management LLC now owns 13,966 shares of the company's stock worth $12,645,000 after purchasing an additional 131 shares during the last quarter. Centaurus Financial Inc. lifted its position in shares of Eli Lilly and Company by 102.4% in the second quarter. Centaurus Financial Inc. now owns 6,099 shares of the company's stock worth $5,522,000 after buying an additional 3,085 shares in the last quarter. Finally, Greater Midwest Financial Group LLC grew its holdings in Eli Lilly and Company by 230.2% during the 2nd quarter. Greater Midwest Financial Group LLC now owns 4,018 shares of the company's stock valued at $3,744,000 after buying an additional 2,801 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research reports. Wolfe Research assumed coverage on Eli Lilly and Company in a research report on Friday, November 15th. They set an "outperform" rating and a $1,000.00 target price for the company. Sanford C. Bernstein began coverage on shares of Eli Lilly and Company in a report on Thursday, October 17th. They issued an "outperform" rating and a $1,100.00 target price on the stock. Citigroup dropped their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday. Redburn Atlantic upgraded Eli Lilly and Company to a "hold" rating in a research report on Monday, November 4th. Finally, Bank of America restated a "buy" rating and set a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $997.22.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm's stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares of the company's stock, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 2.4 %

NYSE LLY opened at $823.59 on Friday. Eli Lilly and Company has a one year low of $637.00 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The company has a market capitalization of $781.85 billion, a price-to-earnings ratio of 89.04, a price-to-earnings-growth ratio of 1.71 and a beta of 0.41. The company's 50-day simple moving average is $780.80 and its two-hundred day simple moving average is $845.98.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period last year, the firm earned $0.10 EPS. The business's quarterly revenue was up 20.4% on a year-over-year basis. Equities analysts forecast that Eli Lilly and Company will post 12.85 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.73%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.30. Eli Lilly and Company's dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company announced that its board has authorized a stock buyback plan on Monday, December 9th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board believes its shares are undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.